HCPCS G2083: Outpatient Visit for Esketamine Nasal Self-Administration - OpenPayer

Summary & Overview

HCPCS G2083: Outpatient Visit for Esketamine Nasal Self-Administration

HCPCS Level II code G2083 represents an outpatient evaluation and management visit for an established patient requiring clinician supervision and provision of greater than 56 mg esketamine nasal self-administration with a two-hour post-administration observation period. This code identifies encounters where supervised administration and extended monitoring are integral to safe medication use and clinical management. Nationally, such codes matter because they standardize reporting for newer, clinic‑based treatments that combine medication delivery with mandated observation, affecting utilization tracking, coverage determinations, and site‑of‑care policies.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical service captured by G2083, typical sites of service, and payer coverage context. The publication outlines what stakeholders can expect regarding billing context, common modifiers in use, and areas where policy guidance or coverage rules are most relevant. The content is organized to support operational, clinical, and reimbursement planning for clinics offering supervised esketamine nasal self-administration for established patients.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareG2083HCPCS Level IIesketamineoutpatient observationE/M visitestablished patientnasal self-administrationbehavioral healthmedication-assisted treatment

Billing Code Overview

HCPCS Level II code G2083 describes an office or other outpatient evaluation and management visit for an established patient when the service requires physician or other qualified health care professional supervision and includes provision of greater than 56 mg esketamine nasal self-administration with 2 hours post-administration observation.

Service type: Outpatient supervised esketamine administration visit with extended observation
Typical site of service: Office or other outpatient clinical setting (includes clinic, ambulatory infusion or observation area)

Clinical & Coding Specifications

Clinical Context

A 42-year-old established patient with treatment-resistant major depressive disorder presents to an outpatient behavioral health infusion/administration clinic for supervised self-administration of esketamine nasal spray. The patient has previously tolerated lower doses and now requires a dose greater than 56 mg per the treatment plan. The visit is scheduled for an office outpatient evaluation and management encounter with a supervising physician or other qualified health care professional present for oversight.

Pre-visit workflow includes verification of indication, review of recent psychiatric assessment, medication reconciliation, baseline vital signs, baseline depression symptom rating (for example, PHQ-9), and confirmation of informed consent and REMS program enrollment. The esketamine nasal device is dispensed and self-administered by the patient in a monitored treatment area. The supervising clinician documents administration and observes the patient for at least 2 hours post-administration for acute adverse events such as dissociation, sedation, blood pressure elevation, or other safety concerns. Post-observation activities include repeat vital signs, assessment for readiness for discharge, scheduling of follow-up dosing or E/M visit, and documentation of any adverse events and patient instructions. Billing uses HCPCS Level II code G2083 for the established patient visit that includes supervision and observation associated with greater than 56 mg esketamine nasal self-administration and a 2-hour post-administration observation period.

Coding Specifications

Modifier	Description	When to Use

HCPCS G2210: Residual Neck Impairment Score, Unmeasured

HCPCS-G0683-LARGE-SKIN-SUBSTITUTE-GRAFT-APPLICATION

HCPCS G0683: Application of Non‑Sheet Skin Substitute Graft, ≥100 sq cm

HCPCS-G8946-BREAST-BIOPSY-ATTEMPT-NONDIAGNOSTIC-HIGH-RISK-LESION

HCPCS G8946: Minimally Invasive Breast Biopsy Attempt, Non-diagnostic

HCPCS-G0504-PSYCHIATRIC-COLLABORATIVE-CARE-MANAGEMENT-ADDITIONAL-30MIN

HCPCS G0504: Psychiatric Collaborative Care Management, Additional 30 Minutes

HCPCS-G0029-TOBACCO-SCREENING-NOT-PERFORMED

HCPCS G0029: Tobacco Screening Not Performed or Cessation Not Provided

HCPCS-G9654-MONITORED-ANESTHESIA-CARE-MAC

HCPCS G9654: Monitored Anesthesia Care (MAC)

HCPCS-G8957-PATIENT-NOT-ON-MAINTENANCE-HEMODIALYSIS-OUTPATIENT-DIALYSIS-FACILITY

HCPCS G8957: Patient Not Receiving Maintenance Hemodialysis in Outpatient Dialysis Facility

HCPCS-G0130-PERIPHERAL-BONE-DENSITY-SEXA

HCPCS G0130: Peripheral Bone Density Study (Single-Energy X-Ray Absorptiometry)

HCPCS-G9918-FUNCTIONAL-STATUS-NOT-PERFORMED

HCPCS G9918: Functional Status Not Performed, Reason NOS

HCPCS-G9321-CT-AND-CARDIAC-NUCLEAR-IMAGING-PRIOR-STUDY-COUNT

HCPCS G9321: Prior CT and Cardiac Nuclear Imaging Study Count

Showing 1–10 of 1996

Taxonomy Code	Specialty	Notes
`103K00000X`	Family Medicine	Primary care physicians who manage ongoing depression treatment and supervise esketamine in outpatient setting.
`2084P0800X`	Psychiatry & Neurology	Psychiatrists who prescribe and supervise esketamine treatment for major depressive disorder.
`282N00000X`	Physician Assistant	PAs who may supervise or co-manage administration under physician supervision in outpatient clinics.
`363A00000X`	Nurse Practitioner	NPs who provide evaluation, monitoring, and supervision for esketamine administration in many clinics.
`367A00000X`	Registered Nurse (RN)	RNs who perform patient monitoring, vital signs, and post-administration observation duties.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`F32.9`	Major depressive disorder, single episode, unspecified	Common indication for esketamine when depression is severe and other treatments have failed.
`F33.1`	Major depressive disorder, recurrent, moderate	Recurrent depressive episodes often prompt consideration of esketamine for treatment-resistant cases.
`F33.2`	Major depressive disorder, recurrent severe without psychotic features	Severe recurrent depression is a typical indication for supervised esketamine administration.
`F32.1`	Major depressive disorder, single episode, moderate	Represents an episode that may escalate to treatment-resistant status and necessitate esketamine.
`F33.8`	Other recurrent depressive disorders	Captures other recurrent depressive presentations treated with esketamine when indicated.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`99213`	Office or other outpatient visit for the evaluation and management of an established patient, typically 15 minutes	May be used for an established patient E/M visit of moderate complexity when billing separate from the esketamine administration visit if payer allows.
`99214`	Office or other outpatient visit for the evaluation and management of an established patient, typically 25 minutes	Used for higher complexity evaluation and management visits that involve substantial decision making or diagnostic management related to esketamine therapy.
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	May be used in workflows where an injectable adjunct or medication is administered during the visit (check payer bundling rules).
`G2086`	Office or other outpatient visit for the evaluation and management of a new patient that requires supervision and provision of esketamine nasal self-administration (includes 2 hours post-administration observation)	Related HCPCS-level counterpart for new patient visits; used in clinics that differentiate new versus established patient billing.
`99406`	Smoking and tobacco-use cessation counseling visit, intermediate, greater than 3 minutes up to 10 minutes	Example of an ancillary counseling service that may be billed separately if provided during the visit and supported by documentation.

OpenPayer